Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2016 - 2023)

Historic Non-Current Deferred Tax Liability for Myriad Genetics (MYGN) over the last 10 years, with Q3 2023 value amounting to $2.7 million.

  • Myriad Genetics' Non-Current Deferred Tax Liability fell 7428.57% to $2.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.7 million, marking a year-over-year decrease of 7428.57%. This contributed to the annual value of $3.5 million for FY2022, which is 9727.84% down from last year.
  • Myriad Genetics' Non-Current Deferred Tax Liability amounted to $2.7 million in Q3 2023, which was down 7428.57% from $3.7 million recorded in Q2 2023.
  • In the past 5 years, Myriad Genetics' Non-Current Deferred Tax Liability ranged from a high of $174.3 million in Q4 2020 and a low of $2.7 million during Q3 2023
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $58.2 million (2021), whereas its average is $52.7 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first surged by 13086.09% in 2020, then crashed by 9727.84% in 2022.
  • Myriad Genetics' Non-Current Deferred Tax Liability (Quarter) stood at $75.5 million in 2019, then surged by 130.86% to $174.3 million in 2020, then decreased by 26.22% to $128.6 million in 2021, then tumbled by 97.28% to $3.5 million in 2022, then fell by 22.86% to $2.7 million in 2023.
  • Its last three reported values are $2.7 million in Q3 2023, $3.7 million for Q2 2023, and $4.1 million during Q1 2023.